Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Income from Continuing Operations (2016 - 2025)

ImmunityBio (IBRX) has disclosed Income from Continuing Operations for 12 consecutive years, with 61958000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations fell 4.7% to 61958000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 351506000.0 through Dec 2025, up 15.02% year-over-year, with the annual reading at 351472000.0 for FY2025, 15.03% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 61958000.0 at ImmunityBio, up from 67274000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 59179000.0 in Q4 2024, with the low at 233414000.0 in Q4 2023.
  • Average Income from Continuing Operations over 5 years is 105808550.0, with a median of 95238500.0 recorded in 2022.
  • The sharpest move saw Income from Continuing Operations crashed 115.47% in 2023, then skyrocketed 74.65% in 2024.
  • Over 5 years, Income from Continuing Operations stood at 91553000.0 in 2021, then fell by 18.32% to 108326000.0 in 2022, then plummeted by 115.47% to 233414000.0 in 2023, then surged by 74.65% to 59179000.0 in 2024, then decreased by 4.7% to 61958000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 61958000.0, 67274000.0, and 92574000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.